Abstract
Protozoan-dependent ailments such as leishmaniasis, malaria and trypanosomiasis continue to be considered as the most neglected diseases, especially among economically deprived populations in developing sub-tropical and tropical belts of Asia, America and Africa. It is also known as the “disease of poverty” as most of the victims belong to the poorest communities. Among the prevalent protozoan parasitic diseases, leishmaniasis ranks second after malaria. Owing to toxicities and adverse effects as well as drug resistance to conventional treatment, new modalities for the treatment of parasitic infections are being continuously explored especially from naturally available bioactive compounds. These have impelled researchers to discover innovative medicines from natural biodiversity as alternative resources from marine environs that are economical, effective, and safe.
Marine environment is recognized with a variety of substances from the classes predominately from invertebrates including tunicates, sponges, bryozoans, molluscs marine cyanobacteria and bacteria, which targets many diseases including the three protozoan diseases mentioned above. As the diseases progress and develop resistance to current treatments, the marine world provides pioneering alternatives against parasitic diseases. The chapter explains the life cycle and geographical distribution of Leishmania, Malaria, and Trypanasoma and the novel marine metabolites that are being exploited for their anti-parasitic activity. Enhanced global awareness regarding the novel anti-infective remedies that are being explored from the incredible diversity of natural marine products will assimilate the augmented efforts to utilize marine products in clinical applications.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Aguiar ACC, Parisi JR, Granito RN, de Sousa LRF, Renno ACM, Gazarini ML (2021) Metabolites from marine sponges and their potential to treat malarial protozoan parasites infection: a systematic review. Mar Drugs 19(3):134. https://doi.org/10.3390/md19030134
Alamgir A (2018) Bioactive compounds and pharmaceutical excipients derived from animals, marine organisms, microorganisms, minerals, synthesized compounds, and pharmaceutical drugs. In: Therapeutic use of medicinal plants and their extracts: volume 2. Springer, Cham, pp 311–406
Ang KK, Holmes MJ, Higa T, Hamann MT, Kara UA (2000) In vivo antimalarial activity of the beta-carboline alkaloid manzamine A. Antimicrob Agents Chemother 44(6):1645–1649. https://doi.org/10.1128/aac.44.6.1645-1649.2000
Aversi-Ferreira R, Galvão JD, da Silva SF, Cavalcante GF, da Silva EV, Bhatia-Dey N et al (2014) Geographical and environmental variables of leishmaniasis transmission. IntechOpen, London
Balunas MJ, Linington RG, Tidgewell K, Fenner AM, Ureña L-D, Togna GD et al (2010) Dragonamide E, a modified linear lipopeptide from Lyngbya majuscula with antileishmanial activity. J Nat Prod 73(1):60–66. https://doi.org/10.1021/np900622m
Belete TM (2020) Recent progress in the development of new antimalarial drugs with novel targets. Drug Des Dev Ther 14:3875–3889. https://doi.org/10.2147/dddt.S265602
Büscher P, Cecchi G, Jamonneau V, Priotto G (2017) Human african trypanosomiasis. Lancet 390(10110):2397–2409
Calvet CM, Silva TA, Thomas D, Suzuki B, Hirata K, Siqueira-Neto JL et al (2020) Long term follow-up of Trypanosoma cruzi infection and Chagas disease manifestations in mice treated with benznidazole or posaconazole. PLoS Negl Trop Dis 14(9):e0008726. https://doi.org/10.1371/journal.pntd.0008726
Carroll AR, Copp BR, Davis RA, Keyzers RA, Prinsep MR (2022) Marine natural products. Nat Prod Rep 37(2):175–223
Cecílio P, Cordeiro-da-Silva A, Oliveira F (2022) Sand flies: basic information on the vectors of leishmaniasis and their interactions with Leishmania parasites. Commun Biol 5(1):305. https://doi.org/10.1038/s42003-022-03240-z
Chen B, Zhao Q, Gu YC, Lan L, Wang CY, Guo YW (2022) Xishaeleganins A-D, sesquiterpenoid hydroquinones from Xisha marine sponge Dactylospongia elegans. Mar Drugs 20(2):118. https://doi.org/10.3390/md20020118
Costello MJ, Chaudhary C (2017) Marine biodiversity, biogeography, deep-sea gradients, and conservation. Curr Biol 27(11):R511–R527
Davies CR, Kaye P, Croft SL, Sundar S (2003) Leishmaniasis: new approaches to disease control. BMJ 326(7385):377–382. https://doi.org/10.1136/bmj.326.7385.377
Davies-Bolorunduro OF, Osuolale O, Saibu S, Adeleye IA, Aminah NS (2021) Bioprospecting marine actinomycetes for antileishmanial drugs: current perspectives and future prospects. Heliyon 7(8):e07710
de Figueiredo IR, Martins M, Midões C, Ferrão JB (2022) Opportunistic infections in the immunocompromised: HIV vs non-HIV patients—a narrative review. HIV Med 10(6):775
Deb RM, Stanton MC, Foster GM, Gupta RKD, Roy N, Das P et al (2018) Visceral leishmaniasis cyclical trends in Bihar, India—implications for the elimination programme. Gates Open Res 2:10
Donia M, Hamann MT (2003) Marine natural products and their potential applications as anti-infective agents. Lancet Infect Dis 3(6):338–348. https://doi.org/10.1016/s1473-3099(03)00655-8
Fattorusso E, Taglialatela-Scafati O (2009) Marine antimalarials. Mar Drugs 7(2):130–152. https://doi.org/10.3390/md7020130
Fattorusso E, Taglialatela-Scafati O (2012) The contribution of marine chemistry in the field of antimalarial research. In: Drug discovery from natural products. Royal Society of Chemistry, Cambridge, pp 374–390
Fenn K, Matthews KR (2007) The cell biology of Trypanosoma brucei differentiation. Curr Opin Microbiol 10(6):539–546
Fletcher SM, Stark D, Harkness J, Ellis J (2012) Enteric protozoa in the developed world: a public health perspective. Clin Microbiol Rev 25(3):420–449. https://doi.org/10.1128/cmr.05038-11
França PH, da Silva-Júnior EF, Santos BV, Alexandre-Moreira MS, Quintans-Junior LJ, de Aquino TM et al (2017) Antileishmanial marine compounds: a review. Rec Nat Prod 11(2):92
Franco JR, Simarro PP, Diarra A, Jannin JG (2014) Epidemiology of human African trypanosomiasis. Clin Epidemiol 6:257
García M, Monzote L (2014) Marine products with anti-protozoal activity: a review. Curr Clin Pharmacol 9(3):258–270
Garrido-Jareño M, Sahuquillo-Torralba A, Chouman-Arcas R, Castro-Hernández I, Molina-Moreno JM, Llavador-Ros M et al (2020) Cutaneous and mucocutaneous leishmaniasis: experience of a Mediterranean hospital. Parasit Vectors 13(1):1–7
Gogineni V, Hamann MT (2018) Marine natural product peptides with therapeutic potential: chemistry, biosynthesis, and pharmacology. Biochim Biophys Acta Gen Subj 1862(1):81–196
Hentschel CC (2002) The medicines for malaria venture. Nature 415(6872):715–715. https://doi.org/10.1038/415715a
Jones AJ, Grkovic T, Sykes ML, Avery VM (2013) Trypanocidal activity of marine natural products. Mar Drugs 11(10):4058–4082
Kang HK, Seo CH, Park Y (2015) Marine peptides and their anti-infective activities. Mar Drugs 13(1):618–654
Kapoor N, Ghorai SM (2021) Role of naturally occurring lead compounds as potential drug targets against malaria. In: Biotechnology in the modern medicinal system. Apple Academic Press, Palm Bay, pp 1–53
König GM, Wright AD, Angerhofer CK (1996) Novel potent antimalarial diterpene isocyanates, isothiocyanates, and isonitriles from the tropical marine sponge Cymbastela hooperi. J Org Chem 61(10):3259–3267
Laniado-Laborín R, Cabrales-Vargas MN (2009) Amphotericin B: side effects and toxicity. Rev Iberoam Micol 26(4):223–227. https://doi.org/10.1016/j.riam.2009.06.003
Legros D, Ollivier G, Gastellu-Etchegorry M, Paquet C, Burri C, Jannin J et al (2002) Treatment of human African trypanosomiasis—present situation and needs for research and development. Lancet Infect Dis 2(7):437–440
Lima ML, Romanelli MM, Borborema SE, Johns DM, Migotto AE, Lago JHG et al (2019) Antitrypanosomal activity of isololiolide isolated from the marine hydroid Macrorhynchia philippina (Cnidaria, Hydrozoa). Bioorg Chem 89:103002
Lindoso JA, Cunha MA, Queiroz IT, Moreira CH (2016) Leishmaniasis-HIV coinfection: current challenges. HIV AIDS (Auckl) 8:147–156. https://doi.org/10.2147/hiv.S93789
Machado de Assis TS, Rabello A, Werneck GL (2012) Predictive models for the diagnostic of human visceral leishmaniasis in Brazil. PLoS Negl Trop Dis 6(2):e1542. https://doi.org/10.1371/journal.pntd.0001542
Malve H (2016) Exploring the ocean for new drug developments: marine pharmacology. J Pharm Bioallied Sci 8(2):83–91. https://doi.org/10.4103/0975-7406.171700
Mancini I, Guella G, Sauvain M, Debitus C, Duigou A-G, Ausseil F et al (2004) New 1,2,3,4-tetrahydropyrrolo [1,2-a] pyrimidinium alkaloids (phloeodictynes) from the New Caledonian shallow-water haplosclerid sponge Oceanapia fistulosa. Structural elucidation from mainly LC-tandem-MS-soft-ionization techniques and discovery of antiplasmodial activity. Org Biomol Chem 2(5):783–787
Martínez-Luis S, Gómez JF, Spadafora C, Guzmán HM, Gutiérrez M (2012) Antitrypanosomal alkaloids from the marine bacterium Bacillus pumilus. Molecules 17(9):11146–11155. https://doi.org/10.3390/molecules170911146
Monroe A, Williams NA, Ogoma S, Karema C, Okumu F (2022) Reflections on the 2021 World Malaria Report and the future of malaria control. Springer, Berlin
Obura DO, Aeby G, Amornthammarong N, Appeltans W, Bax N, Bishop J et al (2019) Coral reef monitoring, reef assessment technologies, and ecosystem-based management. Front Mar Sci 6:580
Orhan I, Sener B, Kaiser M, Brun R, Tasdemir D (2010) Inhibitory activity of marine sponge-derived natural products against parasitic protozoa. Mar Drugs 8(1):47–58. https://doi.org/10.3390/md8010047
Ortega HE, Ferreira LLG, Melo WGP, Oliveira ALL, Ramos Alvarenga RF, Lopes NP et al (2019) Antifungal compounds from Streptomyces associated with attine ants also inhibit Leishmania donovani. PLoS Negl Trop Dis 13(8):e0007643. https://doi.org/10.1371/journal.pntd.0007643
Osterhage C, Kaminsky R, König GM, Wright AD (2000) Ascosalipyrrolidinone a, an antimicrobial alkaloid, from the obligate marine fungus Ascochytas alicorniae. J Org Chem 65(20):6412–6417
Petersen L-E, Kellermann MY, Schupp PJ (2020) Secondary metabolites of marine microbes: from natural products chemistry to chemical ecology. In: Jungblut S, Liebich V, Bode-Dalby M (eds) YOUMARES 9—the oceans: our research, our future: proceedings of the 2018 conference for YOUng MArine RESearcher in Oldenburg, Germany. Springer International Publishing, Cham, pp 159–180. https://doi.org/10.1007/978-3-030-20389-4_8
Ponte-Sucre A, Gamarro F, Dujardin J-C, Barrett MP, López-Vélez R, García-Hernández R et al (2017) Drug resistance and treatment failure in leishmaniasis: a 21st century challenge. PLoS Negl Trop Dis 11(12):e0006052
Prudhomme J, McDaniel E, Ponts N, Bertani S, Fenical W, Jensen P et al (2008) Marine actinomycetes: a new source of compounds against the human malaria parasite. PLoS One 3(6):e2335
Rahman A-U (2002) Studies in natural products chemistry: bioactive natural products, Part H. Elsevier, Amsterdam
Rassi A, de Rezende JM (2012) American trypanosomiasis (Chagas disease). Infect Dis Clin N Am 26(2):275–291
Regalado EL, Tasdemir D, Kaiser M, Cachet N, Amade P, Thomas OP (2010) Antiprotozoal steroidal saponins from the marine sponge Pandaros acanthifolium. J Nat Prod 73(8):1404–1410
Rudrapal M, Chetia D (2016) Endoperoxide antimalarials: development, structural diversity and pharmacodynamic aspects with reference to 1,2,4-trioxane-based structural scaffold. Drug Des Dev Ther 10:3575–3590. https://doi.org/10.2147/dddt.S118116
Sanchez LM, Lopez D, Vesely BA, Della Togna G, Gerwick WH, Kyle DE et al (2010) Almiramides A−C: discovery and development of a new class of Leishmaniasis lead compounds. J Med Chem 53(10):4187–4197. https://doi.org/10.1021/jm100265s
Scala F, Fattorusso E, Menna M, Taglialatela-Scafati O, Tierney M, Kaiser M et al (2010) Bromopyrrole alkaloids as lead compounds against protozoan parasites. Mar Drugs 8(7):2162–2174. https://doi.org/10.3390/md8072162
Sehnal L, Brammer-Robbins E, Wormington AM, Blaha L, Bisesi J, Larkin I et al (2021) Microbiome composition and function in aquatic vertebrates: small organisms making big impacts on aquatic animal health. Front Microbiol 12:567408
Selim MSM, Abdelhamid SA, Mohamed SS (2021) Secondary metabolites and biodiversity of actinomycetes. J Genet Eng Biotechnol 19(1):72. https://doi.org/10.1186/s43141-021-00156-9
Simmons TL, Engene N, Ureña LD, Romero LI, Ortega-Barría E, Gerwick L et al (2008) Viridamides A and B, lipodepsipeptides with antiprotozoal activity from the marine cyanobacterium Oscillatoria nigro-viridis. J Nat Prod 71(9):1544–1550. https://doi.org/10.1021/np800110e
Singh NS, Singh DP (2019) A review on major risk factors and current status of visceral leishmaniasis in north India. Am J Entomol 3(1):6–14
Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI (2005) The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434(7030):214–217
Sundar S, Singh B (2018) Emerging therapeutic targets for treatment of leishmaniasis. Expert Opin Ther Targets 22(6):467–486. https://doi.org/10.1080/14728222.2018.1472241
Teixeira DE, Benchimol M, Rodrigues JC, Crepaldi PH, Pimenta PF, de Souza W (2013) The cell biology of Leishmania: how to teach using animations. PLoS Pathog 9(10):e1003594. https://doi.org/10.1371/journal.ppat.1003594
Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, Arenas R (2017) Leishmaniasis: a review. F1000Res 6:750. https://doi.org/10.12688/f1000research.11120.1
Tougan T, Edula JR, Morita M, Takashima E, Honma H, Tsuboi T et al (2020) The malaria parasite Plasmodium falciparum in red blood cells selectively takes up serum proteins that affect host pathogenicity. Malar J 19(1):1–13
Tyler K, Engman DM (2001) The life cycle of Trypanosoma cruzi revisited. Int J Parasitol 31(5–6):472–481
Valli S, Suvathi SS, Aysha OS, Nirmala P, Vinoth KP, Reena A (2012) Antimicrobial potential of Actinomycetes species isolated from marine environment. Asian Pac J Trop Biomed 2(6):469–473. https://doi.org/10.1016/s2221-1691(12)60078-1
Veerabadhran M, Manivel N, Mohanakrishnan D, Sahal D, Muthuraman S (2014) Antiplasmodial activity of extracts of 25 cyanobacterial species from coastal regions of Tamil Nadu. Pharm Biol 52(10):1291–1301
Venugopal K, Hentzschel F, Valkiūnas G, Marti M (2020) Plasmodium asexual growth and sexual development in the haematopoietic niche of the host. Nat Rev Microbiol 18(3):177–189
Xu M, Andrews KT, Birrell GW, Tran TL, Camp D, Davis RA et al (2011) Psammaplysin H, a new antimalarial bromotyrosine alkaloid from a marine sponge of the genus Pseudoceratina. Bioorg Med Chem Lett 21(2):846–848
Yang F, Hamann MT, Zou Y, Zhang MY, Gong XB, Xiao JR et al (2012) Antimicrobial metabolites from the Paracel Islands sponge Agelas mauritiana. J Nat Prod 75(4):774–778. https://doi.org/10.1021/np2009016
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Khangembam, C.D., Niveria, K., Priyadarshani, A. (2023). Exploring Marine Biodiversity as Alternative Resources for Treatment of Human Parasitic Diseases. In: Singh, A., Rathi, B., Verma, A.K., Singh, I.K. (eds) Natural Product Based Drug Discovery Against Human Parasites. Springer, Singapore. https://doi.org/10.1007/978-981-19-9605-4_5
Download citation
DOI: https://doi.org/10.1007/978-981-19-9605-4_5
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-9604-7
Online ISBN: 978-981-19-9605-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)